drugset / Trial / NCT05404074
Pharmacokinetics of Cobitolimod Enemas in Participants With Active Ulcerative Colitis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the PK, safety and tolerability of cobitolimod ememas (500mg/50mL) given to participants with active left-sided UC.
Timeline
- Start
- 2021-11-22
- Primary completion
- 2022-10-15
- Completion
- 2022-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobitolimod | Oligonucleotide (other) | 500 mg | Rectal |